Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer

Inclusion Criteria: * Male 18 years and older * Histologically confirmed prostate adenocarcinoma * Presence of bone or soft tissue metastasis (by CT or PET or MRI and/or scintigraphy) * Androgen deprivation therapy using Luteinizing-hormone-releasing hormone ( LHRH) analogues commenced at least one month and at most three months prior randomization or orchiectomy performed at least one month and at most three months prior randomization * Serum testosterone level at screening (≤ 1.7 nmol/l, resp. ≤ 50 ng/dL) * Eastern Cooperative Oncology Group (ECOG) 0-2 Exclusion Criteria: * Confirmed brain and/or leptomeningeal metastases * Prior or ongoing chemotherapy for prostate cancer * Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater * Other uncontrolled intercurrent illness * Treatment with immunotherapy against prostate cancer * Clinically significant cardiovascular disease * Active autoimmune disease requiring treatment